Table 3.
Change of initial treatment for IgA nephropathy in Japanese children
| Treatment | Focal mesangial proliferation | Diffuse mesangial proliferation | ||
|---|---|---|---|---|
| 1976–1989 (n = 156) | 1990–2004 (n = 173) | 1976–1989 (n = 63) | 1990–2004 (n = 108) | |
| No treatment | 96 (61.6%) | 23 (13.2%) | 19 (30.2%) | 1 (0.9%) |
| Antiplatelet and/or anticoagulant | 35 (22.4%) | 2 (1.2%) | 14 (22.2%) | 7 (6.5%) |
| Prednisolone, (± antiplatelet and/or anticoagulant) | 4 (2.6%) | 6 (3.5%) | 7 (11.1%) | 25 (23.1%) |
| Prednisolone + immunosuppressant, (± antiplatelet and/or anticoagulant) | 7 (4.5%) | 8 (4.6%) | 19 (30.2%) | 74 (68.5%) |
| Chinese herb (Sairei-to) | 14 (9.0%) | 46 (26.5%) | 4 (6.3%) | 0 (0.0%) |
| ACEI and/or ARB | 0 (0.0%) | 88 (50.9%) | 0 (0.0%) | 1 (0.9%) |
ACEI, Angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker